Exelixis
EXEL
$21.69
Share price
4.38%
Change (1 day)
11.86%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
P/S ratio for Exelixis (EXEL)
P/S ratio as of June 2024 (TTM): 3.28
According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.27787. At the end of 2023 the company had a P/S ratio of 4.08.
P/S ratio history for Exelixis from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 4.08 | 26.93% |
| 2022 | 3.21 | -20.32% |
| 2021 | 4.03 | -36.08% |
| 2020 | 6.31 | 13.98% |
| 2019 | 5.53 | -19.92% |
| 2018 | 6.91 | -65.24% |
| 2017 | 19.9 | -11.96% |
| 2016 | 22.6 | -34.72% |
| 2015 | 34.6 | 207.89% |
| 2014 | 11.2 | -68.88% |
| 2013 | 36.1 | 104.02% |
| 2012 | 17.7 | 698.31% |
| 2011 | 2.22 | -54.29% |
| 2010 | 4.85 | -7.48% |
| 2009 | 5.24 | 16.52% |
| 2008 | 4.50 | -43.54% |
| 2007 | 7.97 | -9.01% |
| 2006 | 8.76 | -15.35% |
| 2005 | 10.3 | -23.26% |
| 2004 | 13.5 | 38.21% |
| 2003 | 9.75 | -9.02% |
| 2002 | 10.7 | -52.9% |
| 2001 | 22.8 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.90 | 18.97% | 🇺🇸 USA |
 Pfizer PFE | 2.90 | -11.51% | 🇺🇸 USA |
 Amgen AMGN | 5.47 | 66.80% | 🇺🇸 USA |
 Sanofi SNY | 2.38 | -27.39% | 🇫🇷 France |
 Merck MRK | 5.19 | 58.44% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.79 | -45.33% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.39 | -27.10% | 🇬🇧 UK |
 Curis CRIS | 6.39 | 94.80% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 5.53 | 68.66% | 🇺🇸 USA |